1 Ocak 2011 Dergi makalesi Açık Erişim

Alicikus, Zumre A.; Yamada, Yoshiya; Zhang, Zhigang; Pei, Xin; Hunt, Margie; Kollmeier, Marisa; Cox, Brett; Zelefsky, Michael J.

MARC21 XML

<?xml version='1.0' encoding='UTF-8'?>
<record xmlns="http://www.loc.gov/MARC21/slim">
  <leader>00000nam##2200000uu#4500</leader>
  <controlfield tag="001">21197</controlfield>
  <datafield tag="540" ind1=" " ind2=" ">
    <subfield code="a">Creative Commons Attribution</subfield>
    <subfield code="u">http://www.opendefinition.org/licenses/cc-by</subfield>
  </datafield>
  <datafield tag="909" ind1="C" ind2="4">
    <subfield code="v">117</subfield>
    <subfield code="p">CANCER</subfield>
    <subfield code="n">7</subfield>
    <subfield code="c">1429-1437</subfield>
  </datafield>
  <controlfield tag="005">20210315104522.0</controlfield>
  <datafield tag="520" ind1=" " ind2=" ">
    <subfield code="a">BACKGROUND. The authors investigated long-term tumor control and toxicity outcomes after high-dose, intensity-modulated radiation therapy (IMRT) in patients who had clinically localized prostate cancer. METHODS. Between April 1996 and January 1998, 170 patients received 81 gray (Gy) using a 5-field IMRT technique. Patients were classified according to the National Comprehensive Cancer Network-defined risk groups. Toxicity data were scored according to the Common Terminology Criteria for Adverse Events Version 3.0. Freedom from biochemical relapse, distant metastases, and cause-specific survival outcomes were calculated. The median follow-up was 99 months. RESULTS. The 10-year actuarial prostate-specific antigen relapse-free survival rates were 81% for the low-risk group, 78% for the intermediate-risk group, and 62% for the high-risk group; the 10-year distant metastases-free rates were 100%, 94%, and 90%, respectively; and the 10-year cause-specific mortality rates were 0%, 3%, and 14%, respectively. The 10-year likelihood of developing grade 2 and 3 late genitourinary toxicity was 11% and 5%, respectively; and the 10-year likelihood of developing grade 2 and 3 late gastrointestinal toxicity was 2% and 1%, respectively. No grade 4 toxicities were observed. CONCLUSIONS. To the authors' knowledge, this report represents the longest followed cohort of patients who received high-dose radiation levels of 81 Gy using IMRT for localized prostate cancer. The findings indicated that high-dose IMRT is well tolerated and is associated with excellent long-term tumor-control outcomes in patients with localized prostate cancer Cancer 2011; 117: 1429-37. (C) 2010 American Cancer Society.</subfield>
  </datafield>
  <datafield tag="245" ind1=" " ind2=" ">
    <subfield code="a">Ten-Year Outcomes of High-Dose, Intensity-Modulated Radiotherapy for Localized Prostate Cancer</subfield>
  </datafield>
  <datafield tag="909" ind1="C" ind2="O">
    <subfield code="p">user-tubitak-destekli-proje-yayinlari</subfield>
    <subfield code="o">oai:zenodo.org:21197</subfield>
  </datafield>
  <datafield tag="542" ind1=" " ind2=" ">
    <subfield code="l">open</subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="u">Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA</subfield>
    <subfield code="a">Alicikus, Zumre A.</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">user-tubitak-destekli-proje-yayinlari</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2=" ">
    <subfield code="z">md5:bac020104bed1455bb93cf062d68c774</subfield>
    <subfield code="s">224</subfield>
    <subfield code="u">https://aperta.ulakbim.gov.trrecord/21197/files/bib-9ea6b9ca-29a9-461f-85ec-318a8601fdbb.txt</subfield>
  </datafield>
  <datafield tag="024" ind1=" " ind2=" ">
    <subfield code="2">doi</subfield>
    <subfield code="a">10.1002/cncr.25467</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA</subfield>
    <subfield code="a">Yamada, Yoshiya</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Mem Sloan Kettering Canc Ctr, Dept Epidemiol &amp; Biostat, New York, NY 10021 USA</subfield>
    <subfield code="a">Zhang, Zhigang</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA</subfield>
    <subfield code="a">Pei, Xin</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10021 USA</subfield>
    <subfield code="a">Hunt, Margie</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA</subfield>
    <subfield code="a">Kollmeier, Marisa</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA</subfield>
    <subfield code="a">Cox, Brett</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="u">Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA</subfield>
    <subfield code="a">Zelefsky, Michael J.</subfield>
  </datafield>
  <datafield tag="650" ind1="1" ind2="7">
    <subfield code="a">cc-by</subfield>
    <subfield code="2">opendefinition.org</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">publication</subfield>
    <subfield code="b">article</subfield>
  </datafield>
  <datafield tag="260" ind1=" " ind2=" ">
    <subfield code="c">2011-01-01</subfield>
  </datafield>
</record>